Updated:
Genome & Company
Genome & Company was established in South Korea's biotechnology hub of Seongnam, where it conducts genomic and microbiome research.
Genome & Company
Genome & Company was established in South Korea's biotechnology hub of Seongnam, where it conducts genomic and microbiome research. The firm's work spans human health, animal nutrition, and agricultural applications, leveraging microbial genomics to develop therapeutic candidates and functional products. The firm's strategy encompasses drug discovery and development, focusing on microbiome modulation for metabolic and immunological conditions. It also partners with academic institutions and contract research organizations to advance preclinical and clinical programs. Geographic footprint centers on Asia, with potential collaborations extending to Europe and North America per public filings. The firm's operational model blends internal research with external licensing and collaborations, though team size and total deployment figures remain undisclosed. No recent operational events have been publicly reported. Genome & Company's structural differentiator lies in its integration of genomics across multiple sectors, from human therapeutics to agritech, a breadth uncommon among specialized biotech entities. Its fund-level governance and succession structure are not publicly documented.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam
Corporate office
Seongnam, South Korea
Sector focus
Frequently asked questions
What is Genome & Company's primary business focus?
Genome & Company applies genomic research to develop microbiome-based therapies and products for human health and agriculture. It operates out of Seongnam, South Korea, and engages in early-stage drug discovery and probiotic development.
Does Genome & Company manage external investor capital?
The firm's ownership and fund structure are not publicly disclosed. It presents as a research-driven entity, but details on whether it functions as an asset manager, family office, or operating company are unavailable in public records.
Which sectors does Genome & Company target?
The firm primarily targets the biotech and life sciences sectors, with specific focus on microbiome modulation for metabolic and immunological diseases, as well as animal nutrition and agricultural probiotics. Its research spans human therapeutics and agritech.
Has Genome & Company disclosed any specific therapeutic candidates?
Public information is limited. The firm's website references genomic platforms and microbiome research, but no named drug candidates or clinical-stage programs have been clearly identified in public records.
Where is Genome & Company headquartered?
Genome & Company is based in Seongnam, South Korea, a city known for its concentration of technology and biotechnology firms in the Gyeonggi Province.
Does Genome & Company have partnerships or collaborations?
The firm's collaboration history is not publicly detailed. Given its research focus, it likely partners with academic institutions and contract research organizations, but no specific partnerships have been confirmed in public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: